AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

Nara Smith shared images and a lengthy caption detailing the health challenges she's experienced in the three years since her ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

The misconception of eczema being contagious likely arises from its association with other infections that can occur among ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Brave Rebecca Ebbage, 31, began breaking out in painful weeping sores when she suddenly stopped using the steroid cream she ...

Researchers believe they’ve discovered the hidden culprit behind eczema itch, paving the way for groundbreaking new treatment ...

Discover how different types of weather, from scorching heat to chilly winds, can wreak havoc on your skin and learn ...

When conventional treatments for moderate to severe atopic dermatitis become less effective, targeted therapies may help.

Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.

Eczema-prone skin needn't mean a mundane moisturiser; our edit includes the ingredient-led, the fragranced and the luxurious ...